Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

Checkit

MCap

GBP23m

Last close

GBP0.21

▲ 1.50 (7.89%)

Claranova

MCap

EUR82m

Last close

EUR1.43

▲ −0.03 (−1.79%)

Boku

MCap

GBP542m

Last close

GBP1.80

▲ 0.00 (0.00%)
Sectors
Sectors
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

Financial Director
Equity Research
Investor Relations
Contact us

Antisense Therapeutics — executive interview with James Garner, chief executive officer

Antisense Therapeutics — executive interview with James Garner, chief executive officer

Antisense Therapeutics — 1 video in collection

More on this equity

Antisense Therapeutics is an Australian biotechnology company developing antisense oligonucleotide therapies for treating rare diseases. Its lead asset, ATL1102, is being investigated as a targeted anti-inflammatory therapy to treat Duchenne muscular dystrophy. In a positive strategic pivot, the trial design was amended to a smaller Phase IIb study (n=42 vs 108) that should provide a nearer-term catalyst, if positive readouts are achieved.

In this video, James Garner, chief executive officer, explains the company’s background and gives an overview of its clinical pipeline.

< Previous

Next >

You may also be interested in these:

Healthcare

29.10.24

Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies

Healthcare

24.10.24

Volition webinar: Nu.Q NETs data insights

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free